Abstract:OBJECTIVE:To evaluate the expression and clinical significance of urinary nuclear matrix protein (NMP22) and cytokeratin 18 (CK18) for transitional cell carcinoma of the bladder.METHODS:Urinary NMP22 and CK18 levels of 293 patients with transitional cell carcinoma of the bladder, 400 patients with non-transitional cell carcinoma of the bladder, and 105 bladder benign disease were analysed by enzyme-linked-immunosorbent assay (ELISA).RESULTS:The levels of urinary NMP22 and CK18 in the patients with transitional cell carcinoma of the bladder (M = 17.3 U/ml, M(CK18) = 484.2 U/L) were significantly higher than those in the non-transitional cell carcinoma of the bladder (M = 6.8 U/ml, M(CK18) = 156.0 U/L) and the benign disease group (M(NMP22) = 2.3 U/ml, M(CK18) = 66.6 U/L) (P < 0.001). The sensitivity and specificity of urinary NMP22 and CK18 were 79.2%, 88.6% and 78.2%, 82.9%, respectively, for transitional cell carcinoma of the bladder before any treatment. The joint sensitivity of the two markers was 91.7%. The NMP22 and CK18 levels were significantly lower in the recovered patients after surgical operation (P < 0.01), while in patients with recurrence or metastasis the levels of the markers were significantly higher (P < 0.01). There was a significant relationship between NMP22 and CK18, (r = 0.689, P < 0.01). The levels of urinary nmp22 and CK18 were significantly different among pathological grade G1, G2, G3, and stage Ta, T1, T2, T3 (P < 0.01).CONCLUSION:NMP22 and CK18 are useful tumor marker for diagnosis of transitional cell carcinoma of the bladder and for monitoring the state of illness. The joint use of the two markers can improve the sensitivity of cancer detection. NMP22 and CK18 may become a new class of tumor markers, and to be the basis for development of a new assay with an increased efficacy for the detection and treatment of bladder cancer.

Studies on Urinary Nuclear Matrix Protein 22 Values in Patients with Transitional Cell Carcinoma of the Bladder

Evaluation of Nuclear Matrix Protein22 (NMP22) in Urine for the Diagnosis of Bladder Transitional Cell Carcinoma

[Expression and Clinical Significance of Nuclear Matrix Protein 22 and Cytokeratin 18 in Transitional Cell Carcinoma of the Bladder].

[Significance of Urinary Nuclear Matrix Protein 22 in Diagnosis of Transitional Cell Carcinoma of Urinary Tract].

The clinical significance of urinary nuclear matrix protein 22 in screening postoperative recurrence of bladder cancer

The Diagnostic and Prognostic Value of Nuclear Matrix Protein 22 in Bladder Cancer

[The Study of Relationship Between Nuclear Metrix Protein 22 Urinary Level and the Grade and Stage of Bladder Transitional Cell Carcinoma].

A clinical evaluation of nuclear matrix protein 22 in urine as an adjuvant diagnostic marker for transitional cell carcinoma of the upper urinary tract

Study of the Expression of CK20 and Ki67 on Cystitis Glandularis of the Urinary Bladder

Nuclear Matrix Protein 22 (Nmp22) Test In The Diagnosis Of Bladder Cancer: A Meta-Analysis

Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma

Comparison of Nuclear Matrix Proteins Between Gastric Cancer and Normal Gastric Tissue

Comparison between nuclear matrix protein 22 (NMP 22) test and voided urine cytology for detection of bladder cancer

NMP22 and BTA stat in the detection of bladder cancer

Microfluidic Assaying of Circulating Tumor Cells and its Correlation with Muscle Invasiveness and Tumor Grade of Urothelial Bladder Cancer

The Role of Nuclear Matrix Protein 22 Combined with Bladder Tumor Antigen Stat Test in Surveillance of Recurring Bladder Cancer.

Nuclear matrix protein 22 in bladder cancer

Detection of Nuclear Matrix Protein 22 and Survivin Baseline Level in Patients after Radical Cystectomy.

The diagnostic efficacy and interference factors of NMP22 in urothelial carcinoma

Urine Cytology and NMP22 Qualitative Assay in Diagnosis of Recurrent Bladder Transitional Cell Carcinoma

Rapid Detection of Bladder Cancer Using a Point-of-care Nuclear Matrix Protein 22 BladderChek Control Kit: a Multicenter Clinical Trial